7298 Upper Clarenton Drive South
89 articles with Aurinia Pharmaceuticals
11/8/2021The first week of November was marked by numerous clinical trial announcements. Here’s a look.
Bristol Myers Squibb’s Phase III CheckMate -816 trial hit the primary endpoint in an interim analysis.
Aurinia Pharmaceuticals Inc. issued its financial results for the third quarter ended September 30, 2021.
Aurinia Announces Updated Interim Results from the AURORA 2 Continuation Study of LUPKYNIS (voclosporin) for the Treatment of Lupus Nephritis
Aurinia Pharmaceuticals Inc. today announced updated interim results from the AURORA 2 continuation study evaluating the long-term safety and tolerability of LUPKYNIS™ (voclosporin) for the treatment of lupus nephritis (LN) in patients with systemic lupus erythematosus (SLE), a chronic and complex autoimmune disease.
GlaxoSmithKline denied reports that they were interested in acquiring Canada’s Aurinia Pharmaceuticals, although some reports claim they are preparing to bid.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that it will release its third quarter 2021 financial results on Wednesday, November 3, 2021, before the markets open.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced that data from multiple studies of LUPKYNIS™ (voclosporin) for the treatment of people with lupus nephritis (LN), a serious complication of systemic lupus erythematosus (SLE) resulting in potentially life-threatening damage to the kidneys, will be presented at American Society of Nephrology (ASN) Kidney Week 2021 and at American College of Rheumatology (ACR) Convergence 2021
Bristol Myers Squibb is reportedly courting Canada's Aurinia Pharmaceuticals to strike a buyout deal.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that members of the senior management team will present at the following upcoming virtual investor conferences:
Aurinia Pharmaceuticals to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
Aurinia Pharmaceuticals Inc. announced the addition of two novel assets that will expand the Company’s rare autoimmune and kidney-related disease pipeline.
The Canadian biotech announced the acquisition of two new pipeline assets that align with its focus on autoimmune and kidney-related disease.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that members of the executive management team will participate in a fireside chat during the Virtual BTIG Annual Biotech Conference on Tuesday, August 10, 2021 at 2:50 p.m. ET.
Aurinia Reports Second Quarter and Six Months 2021 Financial Results and Recent Operational Highlights
Aurinia Pharmaceuticals Inc. issued its financial results for the second quarter ended June 30, 2021.
Aurinia Pharmaceuticals Inc. announced that it will release its second quarter 2021 financial results on Thursday, August 5, 2021, after the markets close.
Aurinia Pharmaceuticals Inc., a commercial stage biopharmaceutical company advancing therapies for severe autoimmune diseases, announced it will voluntarily delist the common shares of the Company from the Toronto Stock Exchange effective as of the close of trading on July 30, 2021.
Aurinia Pharmaceuticals Inc. announced the recipients of five $50,000 grant awards to support implementation patient navigation programs targeted toward disadvantaged populations at most risk of developing SLE and LN.
Aurinia Announces Licensing Partner Otsuka Filed Initial Marketing Authorization Application (MAA) for Voclosporin with the European Medicines Agency (EMA)
Aurinia Pharmaceuticals Inc. announced that the Company’s licensing partner, Otsuka Pharmaceutical Europe Ltd., filed an initial Marketing Authorization Application for voclosporin for the treatment of lupus nephritis to the European Medicines Agency. LN is a complication of the autoimmune disease systemic lupus erythematosus that seriously impacts the kidneys.
Aurinia Pharmaceuticals Inc. announced the appointment of Dr. Brinda Balakrishnan, M.D., Ph.D., to the Company’s Board of Directors effective June 14, 2021.
Aurinia Pharmaceuticals Inc. is pleased to announce that the eight incumbent directors of the Company were elected at the Company’s annual general meeting held on June 7, 2021.